Merus N.V. was acquired by Genmab in December 2025. MRUS no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Genmab, and their dates may not have been updated since.
Clinical trial readout dates for Merus N.V., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is January 2028.
Next readoutJanuary 2028in ~14 months
Upcoming readouts22 Phase 3
Upcoming readouts
Phase 3Petosemtamab (MCLA-158)
PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma
January 2028
Ongoing
Phase 3Petosemtamab (MCLA-158)
Recurrent/metastatic head and neck squamous cell carcinoma